Literature DB >> 12101865

Successful rescue of sustained ventricular tachycardia/ventricular fibrillation after coronary artery bypass grafting by extracorporeal membrane oxygenation.

Robert J Chen1, Wen-Je Ko, Fang-Yue Lin.   

Abstract

Extracorporeal membrane oxygenation (ECMO) can be set up quickly at the bedside and provides reliable temporary mechanical circulatory support for severe heart failure. We report the case of a 56-year-old female with circulatory collapse due to sustained ventricular tachycardia and ventricular fibrillation (VT/Vf) after coronary artery bypass grafting (CABG) who was successfully resuscitated using ECMO. The sustained VT/Vf might have been secondary to myocardial stunning, ischemia, infarction, or reperfusion. There were 40 cardioversions within the first 5 postoperative days. The patient improved after 8 days of ECMO in addition to use of an intraaortic balloon pump and administration of inotropic agents for profound heart failure. Left ventricular ejection fraction improved from 28% preoperatively to 54.5% on the 20th postoperative day. Cardiogenic shock due to sustained VT/Vf after CABG may be an indication for ECMO support. Immediate establishment of circulatory support using ECMO provides valuable time for spontaneous and interventional correction of reversible causes of sustained VT/Vf.

Entities:  

Mesh:

Year:  2002        PMID: 12101865

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  2 in total

Review 1.  Mechanical cardiopulmonary support in children and young adults: extracorporeal membrane oxygenation, ventricular assist devices, and long-term support devices.

Authors:  A C Chang; E D McKenzie
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

2.  A case report of acquired methemoglobinemia rescued by veno-venous extracorporeal membrane oxygenation.

Authors:  Yu-Hsuan Lien; You-Cian Lin; Robert Jeenchen Chen
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.